Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diazepam + indomethacin is a combination of two pharmaceutical agents used together, particularly for the management of night pain and morning stiffness in patients with active rheumatoid arthritis. Diazepam is a long-acting benzodiazepine that acts as an anxiolytic, muscle relaxant, and sedative by enhancing the effect of gamma-aminobutyric acid (GABA) at the GABA-A receptor in the central nervous system. Indomethacin is a nonsteroidal anti-inflammatory drug (NSAID) that exerts its effects primarily through inhibition of cyclooxygenase enzymes (COX-1 and COX-2), leading to decreased synthesis of prostaglandins involved in inflammation, pain, and fever. The combination has been shown to provide superior control over night pain and morning stiffness compared to indomethacin alone in rheumatoid arthritis patients[1][2]. Both drugs may cause dizziness as an additive side effect when used together[5][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on diazepam + indomethacin.